© 2004 European Society for Medical Oncology
Original Article |
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma
Departments of 1 Surgery, 2 Medicine and 3 Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY; 4 Department of Medicine, Dana Farber Cancer Institute, Boston, MA, USA
* Correspondence to: Dr S. Singer, The Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. Tel: +1-212-639-2940; Fax: +1-646-422-2300; Email: singers{at}mskcc.org
Background: The purpose of this study was to retrospectively analyze the relationship between neo-adjuvant chemotherapy (NAC) and outcome in patients with high-grade extremity sarcomas.
Patients and methods: Inclusion criteria were high-grade, deep, >5 cm extremity soft tissue sarcomas. Patients diagnosed between 1990 and 2001 were treated with surgery only (n=282) or NAC containing doxorubicin/ifosfamide/mesna (AIM) (n=74). The stratified Cox proportional hazards model was used to test the effect of NAC on disease-specific survival and recurrence while adjusting for known prognostic factors.
Results: NAC was associated with improved disease-specific survival for this cohort of patients (P=0.02). This overall improvement appears to be driven by the benefit of NAC on disease-specific survival for patient with tumors >10 cm. The 3-year disease-specific survival for tumors >10 cm was 0.62 (95% CI: 0.53–0.71) for patients not receiving NAC and 0.83 (95% CI: 0.72–0.95) for patients receiving NAC.
Conclusion: NAC with AIM was associated with a significant improvement in disease-specific survival in patients with high-grade extremity soft tissue sarcomas >10 cm. These data emphasize the need for further prospective clinical studies of neo-adjuvant or adjuvant chemotherapy for patients with large high-grade extremity sarcomas.
Key words: chemotherapy, doxorubicin, ifosfamide, neo-adjuvant, sarcoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Sternheim, X. Jin, B. Shmookler, J. Jelinek, and M. M. Malawer 'Telangiectatic' Transformation in Soft Tissue Sarcomas. A Clinicopathology Analysis of an Aggressive Feature of High-grade Sarcomas Ann. Surg. Oncol., January 1, 2008; 15(1): 345 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. H. C. Bramwell Controversies in Surgical Oncology: Routine Anthracycline-based Adjuvant Chemotherapy for Stage III Extremity Soft Tissue Sarcoma Ann. Surg. Oncol., April 1, 2007; 14(4): 1254 - 1256. [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Murphey, M. S. Gibson, B. T. Jennings, A. M. Crespo-Rodriguez, J. Fanburg-Smith, and D. A. Gajewski From the Archives of the AFIP: Imaging of Synovial Sarcoma with Radiologic-Pathologic Correlation RadioGraphics, September 1, 2006; 26(5): 1543 - 1565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W.T. Pisters Preoperative Chemotherapy and Split-Course Radiation Therapy for Patients With Localized Soft Tissue Sarcomas: Home Run, Base Hit, or Strike Out? J. Clin. Oncol., February 1, 2006; 24(4): 549 - 551. [Full Text] [PDF]
|
|
|
|
|
|
W. G. Kraybill, J. Harris, I. J. Spiro, D. S. Ettinger, T. F. DeLaney, R. H. Blum, D. R. Lucas, D. C. Harmon, G. D. Letson, and B. Eisenberg Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514 J. Clin. Oncol., February 1, 2006; 24(4): 619 - 625. [Abstract] [Full Text] [PDF]
|
|